Page last updated: 2024-08-25

picropodophyllin and Neoplasm Metastasis

picropodophyllin has been researched along with Neoplasm Metastasis in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Guo, W; Tao, ZZ; Yin, SC	1
Andor, G; Bergqvist, M; Bondarenko, I; Grechanaya, E; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Maximovich, A; Thureson, M	1
All-Ericsson, C; Aström, K; Axelson, M; Economou, MA; Girnita, A; Girnita, L; Larsson, O; Seregard, S	1

Trials

1 trial(s) available for picropodophyllin and Neoplasm Metastasis

Article	Year
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer. Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome	2017

Article

Year

Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.

Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome

2017

Other Studies

3 other study(ies) available for picropodophyllin and Neoplasm Metastasis

Article	Year
Picropodophyllin inhibits tumor growth of human nasopharyngeal carcinoma in a mouse model. Biochemical and biophysical research communications, 2013, Sep-13, Volume: 439, Issue:1 Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Phosphorylation; Podophyllotoxin; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Somatomedins; Xenograft Model Antitumor Assays	2013
Introduction: Uveal melanoma. Acta ophthalmologica, 2008, Volume: 86 Thesis 4 Topics: Administration, Oral; Animals; Humans; Melanoma; Neoplasm Metastasis; Podophyllotoxin; Prognosis; Proto-Oncogene Proteins c-met; Receptor, IGF Type 1; Uveal Neoplasms; Vascular Endothelial Growth Factor A	2008
The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Acta ophthalmologica, 2008, Volume: 86 Thesis 4 Topics: Animals; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Extracellular Matrix Proteins; Humans; Matrix Metalloproteinase Inhibitors; Melanoma; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Phosphorylation; Podophyllotoxin; Receptor, IGF Type 1; Transplantation, Heterologous; Uveal Neoplasms	2008